Lisata Therapeutics, Inc.

3.46 USD
-0.16 (-4.42%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Lisata Therapeutics, Inc. stock is up 24.91% since 30 days ago. The next earnings date is Aug 12, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 43 June’s closed higher than May. 100% of analysts rate it a buy.

About Lisata Therapeutics, Inc.

Caladrius Biosciences, Inc. focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia.